Investigating how Cyclin E1 affects ovarian cancer and potential treatments
The Immunomodulatory Function of Cyclin E1 in Ovarian Cancer and Therapeutic Targeting
This study is looking at how a protein called Cyclin E1 affects high-grade serous ovarian cancer and how it might help us find better treatments for women with this type of cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11053623 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of Cyclin E1 in high-grade serous ovarian cancer (HGSOC), which is a leading cause of cancer-related deaths among women. The study will utilize patient-derived xenograft models to explore how Cyclin E1 influences tumor behavior and response to therapies. By examining the interactions between Cyclin E1 and the immune environment of the tumor, the research aims to identify new therapeutic strategies for patients with specific genetic profiles related to Cyclin E1 expression.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with high-grade serous ovarian cancer, particularly those with Cyclin E1 overexpression or amplification.
Not a fit: Patients with other types of ovarian cancer or those without Cyclin E1 alterations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with high-grade serous ovarian cancer that currently have limited effective therapies.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in ovarian cancer, indicating potential for success in this novel approach.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Ding, Liya — Roswell Park Cancer Institute Corp
- Study coordinator: Ding, Liya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.